Soligenix reports Q3 results, anticipates year-end milestones.

• Soligenix reports Q4 financial results and year-end milestones • Phase 2a trial in mild-to-moderate psoriasis with SGX302 to begin • Enrollment update for Phase 3 study in cutaneous T-cell lymphoma (CTCL) • Data Monitoring Committee concludes first meeting for CTCL study • No major issues or concerns reported from the DMC meeting • Company focused on multiple upcoming milestones before year-end